--- title: "\"Extraordinary Argument - Wen Qiao Fei\" JD Group's performance surged after the results, benefiting from policy support in biomedicine" type: "News" locale: "zh-HK" url: "https://longbridge.com/zh-HK/news/278025364.md" description: "According to the report from \"Feichang Lunzheng,\" Premier Li Qiang proposed an economic growth target of 4.5% to 5% at the National People's Congress. The Hang Seng Index opened high and continued to rise, with biopharmaceutical stocks generally increasing, and 3SBIO rising over 10%. JD.com released its performance report, with revenue increasing by 1.5% year-on-year, but due to losses from new businesses amounting to 2.7 billion yuan, JD Logistics' revenue increased by 22%. Ctrip's stock price rose over 5%, and it will remove the AI pricing assistant to enhance merchant profits" datetime: "2026-03-06T04:08:00.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/278025364.md) - [en](https://longbridge.com/en/news/278025364.md) - [zh-HK](https://longbridge.com/zh-HK/news/278025364.md) --- > 支持的語言: [简体中文](https://longbridge.com/zh-CN/news/278025364.md) | [English](https://longbridge.com/en/news/278025364.md) # "Extraordinary Argument - Wen Qiao Fei" JD Group's performance surged after the results, benefiting from policy support in biomedicine The 14th National People's Congress Fourth Session opened, marking the first year of the "14th Five-Year Plan." Premier Li Qiang delivered the government work report, mentioning that this year's economic growth target is 4.5% to 5%, with 20 key indicators proposed in five areas of economic development and innovation-driven growth. The Hang Seng Index opened high and rose over 400 points, reporting above 25,700 points. The net inflow of short positions in the Hang Seng Index yesterday was 30 million, with a bull-bear certificate street ratio of 61:39. This morning (the 6th), short sellers are still actively counterattacking, with inflows into the newly listed bear certificate 69235 at a recovery price of 25,900 points, while bulls can pay attention to the newly listed bull certificate 69241 at a recovery price of 25,200 points. The government work report for the first time proposed the development of the biopharmaceutical industry as a pillar industry, sending a positive signal for accelerating industrial upgrading. Hong Kong stock biopharmaceutical shares generally opened high this morning, with 3SBIO (01530) rising over 10%, Rongchang Biotech (09995) up 8%, Kangnuo (02162) and Innovent Biologics (01801) up 6%. Those optimistic can pay attention to 3SBIO call option 17493, with an exercise price of 32 HKD, expiring in June 2026; Rongchang call option 23403, with an exercise price of 119 HKD, expiring in October 2026; Kangsheng call option 23855, with an exercise price of 76 HKD, expiring in February 2027; and Innovent call option 23701, with an exercise price of 100 HKD, expiring in August 2026. JD Group released its earnings last night (the 5th). JD (09618) reported a year-on-year revenue increase of 1.5% to 352.3 billion HKD in the last quarter, but turned a loss of 2.7 billion HKD due to new business investments. Total annual revenue exceeded 1.3 trillion HKD for the first time, a year-on-year increase of 13%, with the growth rate reaching a new high for this year. JD Logistics (02618) reported a year-on-year revenue increase of 22% to 63.5 billion HKD in the last quarter, with adjusted profits of 2.35 billion HKD, better than market expectations. JD Logistics surged 18% this morning, while JD also rose over 7%. Pay attention to JD Logistics call option 18207, with an exercise price of 16.8 HKD, expiring in November 2026; JD call option 22618, with an exercise price of 122 HKD, expiring in June 2026; and JD put option 26380, with an exercise price of 96.83 HKD, expiring in September 2026. Trip.com (09961) rose over 5% this morning, surpassing the 400 HKD mark. The company stated it will remove the AI pricing assistant to reduce irrational price competition in the industry and expand merchant profit margins. The announcement also mentioned that the antitrust investigation against Trip.com is still ongoing, and the company is maintaining communication with regulatory authorities regarding compliance matters, currently unable to predict the progress and outcome of the investigation. Trip.com reported its earnings last week, with a year-on-year revenue increase of 21% to 15.4 billion HKD. Institutional analysis indicates that Trip.com's performance is healthy, with revenue exceeding expectations but operating profit margins slightly lagging. Two preparations for Trip.com call option 24774, with an exercise price of 622 HKD, expiring in August 2026; and Trip.com put option 24897, with an exercise price of 360 HKD, expiring in September 2026. "Wen Qiaofei, Sales Director of Derivative Products at Huatai Financial Holdings" - The author is a licensed person of the Securities and Futures Commission and does not hold any of the relevant assets mentioned above. Investors should carefully read and understand the nature, risks, and all details of structured products, as well as information about the issuers (as contained in the relevant listing documents). If necessary, investors should conduct their own risk assessments before investing and seek professional advice regarding the suitability of structured products. - The signed and/or unsigned articles published by "Economic Digest" reflect the personal opinions of the authors and do not represent the position of "Economic Digest." The role of "Economic Digest" is to provide a platform for free speech ### 相關股票 - [First Trust NYSE Arca Biotech Index Fd (FBT.US)](https://longbridge.com/zh-HK/quote/FBT.US.md) - [Yinhua CSI Innovative Drugs Industry ETF (159992.CN)](https://longbridge.com/zh-HK/quote/159992.CN.md) - [Invesco Biotechnology & Genome ETF (PBE.US)](https://longbridge.com/zh-HK/quote/PBE.US.md) - [E Fund Hang Seng SCHK Innovative Drug ETF (159316.CN)](https://longbridge.com/zh-HK/quote/159316.CN.md) - [Invesco Nasdaq Biotechnology ETF (IBBQ.US)](https://longbridge.com/zh-HK/quote/IBBQ.US.md) - [Ark Genomic Revolution ETF (ARKG.US)](https://longbridge.com/zh-HK/quote/ARKG.US.md) - [Bosera Hang Seng Health Care ETF(QDII) (513060.CN)](https://longbridge.com/zh-HK/quote/513060.CN.md) - [ChinaAMC Hang Seng Biotechnology Technology ETF(QDII) (159892.CN)](https://longbridge.com/zh-HK/quote/159892.CN.md) - [Minsheng Royal CSI Biotechnology Theme ETF (516930.CN)](https://longbridge.com/zh-HK/quote/516930.CN.md) - [ChinaAMC CSI Biotechnology Theme ETF (516500.CN)](https://longbridge.com/zh-HK/quote/516500.CN.md) - [E Fund CSI Biotechnology Theme ETF (159837.CN)](https://longbridge.com/zh-HK/quote/159837.CN.md) - [E Fund CSI 300 Health Care ETF (512010.CN)](https://longbridge.com/zh-HK/quote/512010.CN.md) - [iShares US Pharma (IHE.US)](https://longbridge.com/zh-HK/quote/IHE.US.md) - [ALPS Medical Breakthrough (SBIO.US)](https://longbridge.com/zh-HK/quote/SBIO.US.md) - [Huaan Hang Seng Biotech ETF (159102.CN)](https://longbridge.com/zh-HK/quote/159102.CN.md) - [ChinaAMC SSE Health Care ETF Initiating Fund (510660.CN)](https://longbridge.com/zh-HK/quote/510660.CN.md) - [Guotai SSE STAR Brand Name Drug ETF (589720.CN)](https://longbridge.com/zh-HK/quote/589720.CN.md) - [SPDR S&P Biotech (XBI.US)](https://longbridge.com/zh-HK/quote/XBI.US.md) - [Founder Fubon CSI Medicine and Medical Device Innovation ETF (560600.CN)](https://longbridge.com/zh-HK/quote/560600.CN.md) - [JD LOGISTICS (02618.HK)](https://longbridge.com/zh-HK/quote/02618.HK.md) - [Global X E-commerce ETF (EBIZ.US)](https://longbridge.com/zh-HK/quote/EBIZ.US.md) - [Penghua CSI HK Connect Health Care Composite ETF (513700.CN)](https://longbridge.com/zh-HK/quote/513700.CN.md) - [KraneShares 2x Long JD Daily ETF (KJD.US)](https://longbridge.com/zh-HK/quote/KJD.US.md) - [VG Health (VHT.US)](https://longbridge.com/zh-HK/quote/VHT.US.md) - [China Universal 800 Health Care ETF (159929.CN)](https://longbridge.com/zh-HK/quote/159929.CN.md) - [JD-SW (09618.HK)](https://longbridge.com/zh-HK/quote/09618.HK.md) - [Fullgoal Hang Seng SCHK Innovative Drug & Healthcare ETF (159506.CN)](https://longbridge.com/zh-HK/quote/159506.CN.md) - [Health Care Select Sector SPDR (XLV.US)](https://longbridge.com/zh-HK/quote/XLV.US.md) - [China Merchants CSI Biotechnology Theme ETF (159849.CN)](https://longbridge.com/zh-HK/quote/159849.CN.md) - [3SBIO (01530.HK)](https://longbridge.com/zh-HK/quote/01530.HK.md) - [JD HEALTH (06618.HK)](https://longbridge.com/zh-HK/quote/06618.HK.md) - [Hwabao WP Hang Seng SCHK Innovative Drug Select ETF (520880.CN)](https://longbridge.com/zh-HK/quote/520880.CN.md) - [Ping An CSI Medicine and Medical Device Innovation ETF (516820.CN)](https://longbridge.com/zh-HK/quote/516820.CN.md) - [TRIP.COM-S (09961.HK)](https://longbridge.com/zh-HK/quote/09961.HK.md) - [iShares Global Healthcare (IXJ.US)](https://longbridge.com/zh-HK/quote/IXJ.US.md) - [Bosera Hang Seng SCHK Innovative Drug Select ETF (520690.CN)](https://longbridge.com/zh-HK/quote/520690.CN.md) - [iShares Biotechnology ETF (IBB.US)](https://longbridge.com/zh-HK/quote/IBB.US.md) - [Tianhong CNI BIOMEDICINE ETF (159859.CN)](https://longbridge.com/zh-HK/quote/159859.CN.md) - [ICBCCS SSE STAR Biology and Medicine ETF (588860.CN)](https://longbridge.com/zh-HK/quote/588860.CN.md) - [Guotai CSI Bio-medicine ETF (512290.CN)](https://longbridge.com/zh-HK/quote/512290.CN.md) - [China Southern Hang Seng Biotech ETF(QDII) (159615.CN)](https://longbridge.com/zh-HK/quote/159615.CN.md) - [GF CSI HK Innovative Drugs Industry ETF(QDII) (513120.CN)](https://longbridge.com/zh-HK/quote/513120.CN.md) - [ChinaAMC SSE STAR Biology and Medicine ETF (588130.CN)](https://longbridge.com/zh-HK/quote/588130.CN.md) - [VanEck Biotech ETF (BBH.US)](https://longbridge.com/zh-HK/quote/BBH.US.md) - [Proshares Ultra Nasdaq Biotech (BIB.US)](https://longbridge.com/zh-HK/quote/BIB.US.md) - [Penghua SSE STAR Biology and Medicine ETF (588250.CN)](https://longbridge.com/zh-HK/quote/588250.CN.md) - [JD.com (JD.US)](https://longbridge.com/zh-HK/quote/JD.US.md) ## 相關資訊與研究 - [JD.com Prices 10 Billion Yuan Offshore Bond Offering](https://longbridge.com/zh-HK/news/281445627.md) - [JD.com Plans Offshore CNY Bond Offering to Refinance Debt](https://longbridge.com/zh-HK/news/281116889.md) - [Key facts: Citi expects JD will cut losses 2026; JD buys $450M HK tower](https://longbridge.com/zh-HK/news/281488305.md) - [Annovis Bio Director Purchased Shares Worth Over $1.4M](https://longbridge.com/zh-HK/news/281662341.md) - [JD.com Announces Pricing of CNY10 Billion CNY-denominated Senior Notes | JD Stock News](https://longbridge.com/zh-HK/news/281432814.md)